MIRM
Income statement / Annual
Last year (2023), Mirum Pharmaceuticals, Inc.'s total revenue was $186.37 M,
an increase of 141.85% from the previous year.
In 2023, Mirum Pharmaceuticals, Inc.'s net income was -$163.42 M.
See Mirum Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
Operating Revenue |
$186.37 M
|
$77.06 M
|
$19.14 M
|
$0.00
|
$0.00
|
$0.00
|
Cost of Revenue |
$47.37 M |
$12.37 M |
$1.90 M |
$623,000.00 |
$324,000.00 |
$0.00 |
Gross Profit |
$139.01 M |
$64.69 M |
$17.24 M |
-$623,000.00 |
-$324,000.00 |
$0.00 |
Gross Profit Ratio |
0.75 |
0.84 |
0.9 |
0 |
0 |
0 |
Research and Development
Expenses |
$102.28 M
|
$106.84 M
|
$131.43 M
|
$81.61 M
|
$42.99 M
|
$2.33 M
|
General & Administrative
Expenses |
$139.58 M
|
$16.96 M
|
$59.22 M
|
$22.69 M
|
$11.75 M
|
$877,500.00
|
Selling & Marketing
Expenses |
$6.30 M
|
$72.11 M
|
$9.20 M
|
$0.00
|
$0.00
|
-$292,500.00
|
Selling, General &
Administrative Expenses |
$145.88 M
|
$89.07 M
|
$59.22 M
|
$22.69 M
|
$11.75 M
|
$585,000.00
|
Other Expenses |
-$2.82 M |
$365,000.00 |
$107.42 M |
-$192,000.00 |
-$21,000.00 |
$0.00 |
Operating Expenses |
$248.16 M |
$195.91 M |
$190.65 M |
$104.30 M |
$54.74 M |
$2.92 M |
Cost And Expenses |
$295.53 M |
$208.28 M |
$192.55 M |
$104.30 M |
$54.74 M |
$2.92 M |
Interest Income |
$13.74 M |
$3.86 M |
$366,000.00 |
$1.56 M |
$2.23 M |
$87,000.00 |
Interest Expense |
$15.11 M |
$15.98 M |
$17.59 M |
$335,000.00 |
$0.00 |
$0.00 |
Depreciation &
Amortization |
$10.83 M
|
$3.68 M
|
$975,000.00
|
$623,000.00
|
$324,000.00
|
$4.37 M
|
EBITDA |
-$98.33 M
|
-$127.00 M
|
-$64.65 M
|
-$102.93 M
|
-$54.74 M
|
-$2.92 M
|
EBITDA Ratio |
-0.53 |
-1.65 |
-3.38 |
0 |
0 |
0 |
Operating Income Ratio
|
-0.59
|
-1.7
|
-9.06
|
0
|
0
|
0
|
Total Other
Income/Expenses Net |
-$53.27 M
|
-$10.85 M
|
$89.46 M
|
$1.03 M
|
$2.21 M
|
-$14.43 M
|
Income Before Tax |
-$162.42 M |
-$142.07 M |
-$83.95 M |
-$103.26 M |
-$52.53 M |
-$17.35 M |
Income Before Tax Ratio
|
-0.87
|
-1.84
|
-4.39
|
0
|
0
|
0
|
Income Tax Expense |
$991,000.00 |
-$6.41 M |
$37,000.00 |
$6,000.00 |
$21,000.00 |
-$4.37 M |
Net Income |
-$163.42 M |
-$135.67 M |
-$83.99 M |
-$103.27 M |
-$52.55 M |
-$17.35 M |
Net Income Ratio |
-0.88 |
-1.76 |
-4.39 |
0 |
0 |
0 |
EPS |
-4 |
-4.01 |
-2.77 |
-4.09 |
-2.29 |
-0.75 |
EPS Diluted |
-4 |
-4.01 |
-2.77 |
-4.09 |
-2.29 |
-0.75 |
Weighted Average Shares
Out |
$40.89 M
|
$33.84 M
|
$30.32 M
|
$25.25 M
|
$22.99 M
|
$22.99 M
|
Weighted Average Shares
Out Diluted |
$40.89 M
|
$33.84 M
|
$30.32 M
|
$25.25 M
|
$22.99 M
|
$22.99 M
|
Link |
|
|
|
|
|
|